Recursion Pharmaceuticals is a biotechnology business based in the US. Recursion Pharmaceuticals shares (RXRX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.93 – a decrease of 3.9% over the previous week. Recursion Pharmaceuticals employs 800 staff and has a trailing 12-month revenue of around $59.8 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $4.93 |
|---|---|
| 52-week range | $3.79 - $12.36 |
| 50-day moving average | $4.87 |
| 200-day moving average | $6.30 |
| Wall St. target price | $7.14 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.80 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.93 from 2025-07-07
| 1 week (2025-07-02) | -5.37% |
|---|---|
| 1 month (2025-06-10) | -9.54% |
| 3 months (2025-04-10) | 9.31% |
| 6 months (2025-01-10) | -28.34% |
| 1 year (2024-07-10) | -31.81% |
|---|---|
| 2 years (2023-07-07) | -28.13% |
| 3 years (2022-07-08) | 8.96 |
| 5 years (2020-07-06) | N/A |
| Revenue TTM | $59.8 million |
|---|---|
| Gross profit TTM | $-372,606,016 |
| Return on assets TTM | -38.51% |
| Return on equity TTM | -86.1% |
| Profit margin | 0% |
| Book value | $2.30 |
| Market Capitalization | $2.2 billion |
TTM: trailing 12 months
We're not expecting Recursion Pharmaceuticals to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Recursion Pharmaceuticals's shares have ranged in value from as little as $3.79 up to $12.36. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Recursion Pharmaceuticals's is 0.833. This would suggest that Recursion Pharmaceuticals's shares are less volatile than average (for this exchange).
To put Recursion Pharmaceuticals's beta into context you can compare it against those of similar companies.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Discover the best stock picking services based on expert analysis, pricing, and strategy fit. Compare top tools to find the right service for your investing style in 2025.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
We’ve rounded up stats on some of the most popular oil stocks, along with information on how they compare and how to invest.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
Compare pros, cons, research tools and reviews for these two trading platforms.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .